Concepedia

Daniele Rizzi

DR

Statistics

Publications

11

Citations

782

H-Index

10

Active since

2014

Affiliations

Casa Sollievo della Sofferenza(Current)

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Ospedale A. Perrino

Istituti di Ricovero e Cura a Carattere Scientifico

University of Campania "Luigi Vanvitelli"

Daniele Rizzi is an author at Casa Sollievo della Sofferenza specializing in oncology, medicine, and radiation oncology.

Top concepts

Publications per year

2014–2020

11

Publications

11

Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial

Nicola Normanno, Anna Maria Rachiglio, Matilde Lambiase et al. · Annals of Oncology · 2015 · 145 citations · Full text

, , +8

RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial

Nicola Normanno, Riziero Esposito Abate, Matilde Lambiase et al. · Annals of Oncology · 2017 · 117 citations

Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial

Fortunato Ciardiello, Nicola Normanno, Evaristo Maiello et al. · Annals of Oncology · 2014 · 116 citations · Full text

, , +11

Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX

Fortunato Ciardiello, Nicola Normanno, Erika Martinelli et al. · Annals of Oncology · 2016 · 97 citations

, , +8

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 86 citations · Full text

, , +7

1–5 of 11